One-stage versus two-stage amputation for wet gangrene of the lower extremity: a randomized study.
Although the two-stage amputation technique entails an additional operation, several authors have advocated this approach to deal with wet gangrene because it allows primary wound closure with a reduced chance of wound infection. To examine this issue, 47 patients with necrotizing wet gangrene of the foot were randomized prospectively to receive either a one-stage amputation (definitive below- or above-knee amputation with delayed secondary skin closure in 3 to 5 days) or a two-stage amputation (open ankle guillotine amputation followed by definitive, closed below- or above-knee amputation). Antibiotic coverage was standardized with clindamycin and gentamicin used in all patients. Preoperative blood cultures and intraoperative foot cultures were obtained, as well as cultures from the deep muscle and lymphatic area along the saphenous vein to determine the presence of bacteria at the level of initial amputation. Twenty-four patients (11 diabetic and 13 nondiabetic) were randomized to the one-stage procedure. Twenty-three patients (14 diabetic and nine nondiabetic) were randomized to the two-stage procedure. Five of 24 patients in the one-stage group (21%) had positive muscle cultures vs 10 of 23 patients in the two-stage group (43%). Two of 24 patients in the one-stage group (8%) had positive lymphatic cultures vs 7 of 23 patients in the two-stage group (30%). Five of 24 patients in the one-stage group (21%) had wound complications attributable to the amputation technique vs none of 23 patients in the two-stage group (p = 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
Fisher
D F
DF
Department of Surgery, University of Texas Southwestern Medical Center, Dallas 75235-9031.
Clagett
G P
GP
Fry
R E
RE
Humble
T H
TH
Fry
W J
WJ
D000368:Aged; D000671:Amputation, Surgical / Q000379:methods*; D002981:Clindamycin / Q000627:therapeutic use; D005534:Foot Diseases / Q000601:surgery*; D005734:Gangrene / Q000601:surgery*; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D011292:Premedication; D011446:Prospective Studies; D011897:Random Allocation; D012086:Reoperation; D013530:Surgical Wound Infection / Q000517:prevention & control
D005839:Gentamicins; D002981:Clindamycin